Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation.
Animals
Biological Availability
Delayed-Action Preparations
Drug Compounding
/ methods
Hydrogen-Ion Concentration
Infusions, Parenteral
Injections, Subcutaneous
Male
Methylcellulose
/ chemistry
Ondansetron
/ administration & dosage
Particle Size
Plant Oils
/ chemistry
Rats
Solubility
Suspensions
Viscosity
Microparticles
Oil suspension
Ondansetron hydrochloride
Parenteral formulation
Spray drying
Sustained release
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
30
10
2019
medline:
6
10
2020
entrez:
30
10
2019
Statut:
ppublish
Résumé
Ondansetron hydrochloride (ODS) is a selective 5-hydroxytryptamine type 3 antagonist for nausea and emesis prevention in neoplastic patients. To reduce dosing frequency and side effects and improve patient compliance, a sustained release parenteral formulation of ODS was developed. Microparticles of methylcellulose (MC) and ODS were prepared using the spray-drying method and suspended in oils to form oil suspensions. The formulations were evaluated for residual moisture, drug content, size distribution, DSC, XRD, FTIR, SEM, drug release, and pharmacokinetic studies. The effects of polymers and oils on the drug release were evaluated. MC showed the most prominent sustained release effect among various polymers examined with the optimum MC/ODS ratio of 2:1 (w/w). The particle size of the produced microparticles was in the mean diameter of approximately 3 μm. Physicochemical characterization suggested that ODS existed in an amorphous matrix within the microparticles and interacted with MC via hydrogen bonds. Corn oil was selected as the appropriate oil for suspension due to the sustained release of ODS and the appropriate viscosity. The optimized sustained release formulation of ODS was the corn oil suspension of spray-dried microparticles containing MC and ODS (2:1, w/w). It showed an in vitro drug sustained release up to 120 h, while the oil suspension of ODS without any polymer released the drug within 2 h. Following subcutaneous administration in rats, the optimized formulation could prolong the drug release until 72 h with the enhanced bioavailability in comparison with the ODS solution. The oil suspension of spray-dried microparticles might be an efficient approach for prolongation of the drug effect in the management of nausea and emesis. Graphical abstract.
Identifiants
pubmed: 31659599
doi: 10.1007/s13346-019-00687-2
pii: 10.1007/s13346-019-00687-2
doi:
Substances chimiques
Delayed-Action Preparations
0
Plant Oils
0
Suspensions
0
Ondansetron
4AF302ESOS
Methylcellulose
9004-67-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
282-295Références
Drug Des Devel Ther. 2015 Aug 12;9:4621-9
pubmed: 26316701
J Young Pharm. 2010 Jul;2(3):240-6
pubmed: 21042478
Carbohydr Polym. 2014 Jan 30;101:171-8
pubmed: 24299762
J Control Release. 2017 Jul 28;258:226-253
pubmed: 28472638
Drug Deliv Transl Res. 2020 Feb;10(1):1-12
pubmed: 31144213
J Vet Pharmacol Ther. 2014 Aug;37(4):348-53
pubmed: 24330064
J Pharm Sci. 2011 Feb;100(2):566-79
pubmed: 20799364
AAPS J. 2009 Dec;11(4):762-70
pubmed: 19894123
Pharm Res. 2019 Jul 26;36(10):138
pubmed: 31350675
Drug Deliv. 2015;22(7):894-902
pubmed: 24279581
Drug Deliv Transl Res. 2016 Dec;6(6):648-659
pubmed: 27807769
AAPS J. 2010 Sep;12(3):263-71
pubmed: 20373062
J Mater Sci Mater Med. 2012 Sep;23(9):2163-75
pubmed: 22802103
J Control Release. 2014 Nov 28;194:316-22
pubmed: 25245775
J Pharm Biomed Anal. 2018 Jan 30;148:73-79
pubmed: 28965047
Drug Deliv Transl Res. 2020 Feb;10(1):202-215
pubmed: 31482519
Drugs. 2016 Dec;76(18):1779-1786
pubmed: 27915445
Biopharm Drug Dispos. 2010 Oct;31(7):407-27
pubmed: 20848388
Biopharm Drug Dispos. 2008 Oct;29(7):414-26
pubmed: 18697186
Int J Nanomedicine. 2014 Jul 25;9:3527-38
pubmed: 25114523
J Control Release. 2005 May 18;104(2):323-35
pubmed: 15907583
Pharm Res. 2008 May;25(5):999-1022
pubmed: 18040761
Drug Deliv Transl Res. 2020 Feb;10(1):122-135
pubmed: 31444736
Arch Pharm Res. 2018 Feb;41(2):111-129
pubmed: 29214601
Pharm Dev Technol. 2000;5(2):267-78
pubmed: 10810756
J Exp Pharmacol. 2014 Dec 09;6:15-21
pubmed: 27186139
J Microencapsul. 2011;28(2):108-21
pubmed: 21265712
Drug Deliv Transl Res. 2018 Jun;8(3):693-701
pubmed: 29600480
Int J Pharm. 2008 Feb 12;349(1-2):101-7
pubmed: 17822864
Eur J Pharm Biopharm. 2008 Jun;69(2):735-42
pubmed: 18291632
J Pharm Sci. 1996 Apr;85(4):396-401
pubmed: 8901076
Pharm Res. 2004 Aug;21(8):1374-81
pubmed: 15359571
Eur J Pharm Sci. 2000 Sep;11(3):231-7
pubmed: 11042229
Clin Pharmacokinet. 1995 Aug;29(2):95-109
pubmed: 7586904
Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):437-44
pubmed: 24471415
Drug Deliv Transl Res. 2019 Feb;9(1):319-333
pubmed: 30276666
Drug Dev Ind Pharm. 2008 Nov;34(11):1178-87
pubmed: 18777240
N Engl J Med. 2016 Apr 7;374(14):1356-67
pubmed: 27050207
Drug Deliv Transl Res. 2017 Feb;7(1):132-146
pubmed: 27924469
Drug Deliv Transl Res. 2018 Oct;8(5):1274-1288
pubmed: 30112607
Drug Deliv Transl Res. 2020 Feb;10(1):159-167
pubmed: 31468307
Drug Deliv Transl Res. 2018 Jun;8(3):670-692
pubmed: 29589250